Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Chronic Idiopathic Pruritus
NCT03239106Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apremilast in chronic idiopathic pruritus, sponsored by Washington University School of Medicine. Started Dec 2017; status: completed.
02
Drugs
apremilast
03
Conditions
chronic idiopathic pruritus
Beyond the preview
Go deeper on NCT03239106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239106.